Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1084394

registered interest
date	08/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he will report to Parliament annually on the operation of the Voluntary Scheme for Branded Medicines Pricing and Access; and whether such reporting will extend to the operation of the statutory pricing scheme.
tabling member constituency	Newton Abbot
tabling member printed	Anne Marie Morris
uin	230052
answer	answer is ministerial correction date of answer 13/03/2019 answer text <p>The Department has agreed that the 2019 Voluntary Scheme for Branded Medicines Pricing and Access will be subject to regular six-monthly reviews and a mid-scheme review with all parties to the agreement expected to attend.</p><p> </p><p>The Department already produces quarterly reports on the operation of the voluntary and statutory schemes and this is set to continue. The relevant statutory scheme regulations require an annual review of the scheme, which will be made available to Parliament on an annual basis.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 13/03/2019 14:17:16 answering member 4067 label Biography information for Steve Brine
tabling member	4249 label Biography information for Anne Marie Morris

1077148

registered interest
date	25/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the 2019 Voluntary scheme for branded medicines pricing and access, what plans NHS England has to consult patient organisations on the new commercial framework which is being developed.
tabling member constituency	Enfield, Southgate
tabling member printed	Bambos Charalambous
uin	225602
answer	answer is ministerial correction date of answer 28/02/2019 answer text <p>NHS England, together with the National Institute for Health and Care Excellence, is developing a ’commercial framework’ setting out the parameters for the commercial approach for medicines in the health service in England. This framework will be tested with and informed through consultation with stakeholders. In preparation for public consultation in the coming months, NHS England is actively engaging with industry trade bodies and health system partners, in the first instance, to progress the development of the commercial framework, as set out in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 28/02/2019 16:23:38 answering member 4067 label Biography information for Steve Brine
tabling member	4610 label Biography information for Bambos Charalambous

1064732

registered interest
date	21/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 12 February 2019 to Question 220230 on NHS: Drugs, whether he has plans to undertake a public consultation on the proposed Framework.
tabling member constituency	Newton Abbot
tabling member printed	Anne Marie Morris
uin	224335
answer	answer is ministerial correction date of answer 28/02/2019 answer text <p>NHS England, together with the National Institute for Health and Care Excellence, is developing a ’commercial framework’ setting out the parameters for the commercial approach for medicines in the health service in England. This framework will be tested with and informed through consultation with stakeholders. In preparation for public consultation in the coming months, NHS England is actively engaging with industry trade bodies and health system partners, in the first instance, to progress the development of the commercial framework, as set out in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 28/02/2019 16:19:39 answering member 4067 label Biography information for Steve Brine
tabling member	4249 label Biography information for Anne Marie Morris

1064350

registered interest
date	20/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 8 February 2019 to Question 215257, on NHS: drugs, what information his Department holds on the level of medicine shortages in the last 12 months.
tabling member constituency	Kensington
tabling member printed	Emma Dent Coad
uin	223824
answer	answer is ministerial correction date of answer 26/02/2019 answer text <p>Medicines shortages are a routine issue that the Department constantly manages. The Department works closely with the Medicines and Healthcare products Regulatory Agency (MHRA), the pharmaceutical industry, NHS England and others operating in the supply chain to ensure that the risks to patients are minimised when they do arise.</p><p> </p><p>The Department receives regular reports from the pharmaceutical industry about impending medicine supply issues that may affect United Kingdom patients. From January 2019, it became a mandatory requirement that the pharmaceutical industry must report this information to us in a timely manner. However, not all the issues of which the Department are notified will result in a medicine shortage as the supply team will work behind the scenes using a host of tools to help mitigate and prevent an issue from impacting patients.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 26/02/2019 15:30:37 answering member 4067 label Biography information for Steve Brine
tabling member	4683 label Biography information for Emma Dent Coad

1063785

registered interest
date	18/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what definition will be used by the Government to determine a serious shortage of a medicine that will be used to trigger a Serious Shortage Protocol for a medicine under the Human Medicines (Amendment) Regulations 2019.
tabling member constituency	Sunderland Central
tabling member printed	Julie Elliott
uin	222720
answer	answer is ministerial correction date of answer 21/02/2019 answer text <p>The Department has well established processes to manage and mitigate the small number of medicine supply problems that may arise at any one time due to manufacturing or distribution issues and this has always been the case. The Department receives regular reports from the pharmaceutical industry about issues which may potentially interrupt the supply of medicines that may affect United Kingdom patients.</p><p>From January this year, it became a mandatory requirement that pharmaceutical companies must report this information to us in a timely manner.</p><p>A Serious Shortage Protocol (SSP) is an additional tool to manage and mitigate medicine shortages. It would only be used in the exceptional and rare situation when other measures have been exhausted or are likely to be ineffective.</p><p>In the case of a serious shortage, a SSP would only be issued by Ministers if clinicians advised that it was appropriate and after discussion with the manufacturer and/or marketing authorisation holder.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 222723 222724 222725 question first answered 21/02/2019 16:16:26 answering member 4067 label Biography information for Steve Brine
tabling member	4127 label Biography information for Julie Elliott

1063788

registered interest
date	18/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what data source will be used to monitor stocks and availability of medicines in order to determine the need for a Serious Shortage Protocol under the Human Medicines (Amendment) Regulations 2019.
tabling member constituency	Sunderland Central
tabling member printed	Julie Elliott
uin	222723
answer	answer is ministerial correction date of answer 21/02/2019 answer text <p>The Department has well established processes to manage and mitigate the small number of medicine supply problems that may arise at any one time due to manufacturing or distribution issues and this has always been the case. The Department receives regular reports from the pharmaceutical industry about issues which may potentially interrupt the supply of medicines that may affect United Kingdom patients.</p><p>From January this year, it became a mandatory requirement that pharmaceutical companies must report this information to us in a timely manner.</p><p>A Serious Shortage Protocol (SSP) is an additional tool to manage and mitigate medicine shortages. It would only be used in the exceptional and rare situation when other measures have been exhausted or are likely to be ineffective.</p><p>In the case of a serious shortage, a SSP would only be issued by Ministers if clinicians advised that it was appropriate and after discussion with the manufacturer and/or marketing authorisation holder.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 222720 222724 222725 question first answered 21/02/2019 16:16:26 answering member 4067 label Biography information for Steve Brine
tabling member	4127 label Biography information for Julie Elliott

1063789

registered interest
date	18/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the Human Medicines (Amendment) Regulations 2019, what process will be followed to consult with relevant health care professionals in the development of advice contained in a Serious Shortage Protocol.
tabling member constituency	Sunderland Central
tabling member printed	Julie Elliott
uin	222724
answer	answer is ministerial correction date of answer 21/02/2019 answer text <p>The Department has well established processes to manage and mitigate the small number of medicine supply problems that may arise at any one time due to manufacturing or distribution issues and this has always been the case. The Department receives regular reports from the pharmaceutical industry about issues which may potentially interrupt the supply of medicines that may affect United Kingdom patients.</p><p>From January this year, it became a mandatory requirement that pharmaceutical companies must report this information to us in a timely manner.</p><p>A Serious Shortage Protocol (SSP) is an additional tool to manage and mitigate medicine shortages. It would only be used in the exceptional and rare situation when other measures have been exhausted or are likely to be ineffective.</p><p>In the case of a serious shortage, a SSP would only be issued by Ministers if clinicians advised that it was appropriate and after discussion with the manufacturer and/or marketing authorisation holder.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 222720 222723 222725 question first answered 21/02/2019 16:16:26 answering member 4067 label Biography information for Steve Brine
tabling member	4127 label Biography information for Julie Elliott

1063790

registered interest
date	18/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the Human Medicines (Amendment) Regulations 2019, what methods the Government plans to use to whether a Serious Shortage Protocol is necessary; what information such a decision would be based on; what level of consultation with medical experts the Government plans to seek on such protocols; and how the Government plans to engage in such consultation.
tabling member constituency	Sunderland Central
tabling member printed	Julie Elliott
uin	222725
answer	answer is ministerial correction date of answer 21/02/2019 answer text <p>The Department has well established processes to manage and mitigate the small number of medicine supply problems that may arise at any one time due to manufacturing or distribution issues and this has always been the case. The Department receives regular reports from the pharmaceutical industry about issues which may potentially interrupt the supply of medicines that may affect United Kingdom patients.</p><p>From January this year, it became a mandatory requirement that pharmaceutical companies must report this information to us in a timely manner.</p><p>A Serious Shortage Protocol (SSP) is an additional tool to manage and mitigate medicine shortages. It would only be used in the exceptional and rare situation when other measures have been exhausted or are likely to be ineffective.</p><p>In the case of a serious shortage, a SSP would only be issued by Ministers if clinicians advised that it was appropriate and after discussion with the manufacturer and/or marketing authorisation holder.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 222720 222723 222724 question first answered 21/02/2019 16:16:26 answering member 4067 label Biography information for Steve Brine
tabling member	4127 label Biography information for Julie Elliott

1061232

registered interest
date	14/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of trends in the level of the (a) availability of (i) Lossartin, (ii) Furosemide and (iii) Nicarindil and (b) prices beyond the NHS tariff that community pharmacies have been charged by the suppliers of those products since September 2018.
tabling member constituency	Birmingham, Northfield
tabling member printed	Richard Burden
uin	221587
answer	answer is ministerial correction date of answer 19/02/2019 answer text <p>The Department is not aware of issues affecting the availability of losartan, furosemide or nicorandil tablets and can confirm that supplies of these three medicines are currently available. We are aware that there was a short-term supply issue affecting furosemide 20mg and 40mg towards the end of 2018 due to manufacturing delays, but this issue has now been resolved and supplies remain available.</p><p> </p><p>When community pharmacies cannot purchase a medicine at or below the reimbursement price listed in the Drug Tariff, the Pharmaceutical Services Negotiating Committee (the representative body of pharmacies), drawing on reports they receive from pharmacy contractors, can request the Department to consider setting a concessionary price.</p><p> </p><p>When considering whether to grant a concessionary price, the Department uses market data from suppliers, i.e. manufacturers and wholesalers on prices and stock levels intended for retail pharmacy businesses in England. If granted, a concessionary price applies only to prescriptions dispensed for the month for which it was granted.</p><p> </p><p>From September 2018 onwards, the trends for these generic medicines that have been granted concessionary prices can be seen in the attached tables.</p><p> </p><p>It should be noted that as concessionary prices for February are still in process, no prices have been published yet. More information on the list of concessionary prices granted for each month can be found at the following link:</p><p> </p><p><a href="https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/drug-tariff/drug-tariff-updates" target="_blank">https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/drug-tariff/drug-tariff-updates</a></p><p /><p /> answering member constituency Winchester answering member printed Steve Brine question first answered 19/02/2019 17:22:23 answering member 4067 label Biography information for Steve Brine attachment 1 file name PQ221587 attached tables.docx title PQ221587 attached tables
tabling member	301 label Biography information for Richard Burden

1059822

registered interest
date	12/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to paragraph 3.27 of the 2019 voluntary scheme for branded medicines pricing and access, whether NHS England will issue a public consultation on a proposed new commercial framework.
tabling member constituency	Newton Abbot
tabling member printed	Anne Marie Morris
uin	220230
answer	answer is ministerial correction date of answer 18/02/2019 answer text <p>NHS England, together with the National Institute for Health and Care Excellence is developing a ’commercial framework’ setting out the parameters for the commercial approach for medicines in the health service in England. This framework will be tested with and informed through consultation with stakeholders. The intention is to publish the framework early in 2019.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/02/2019 17:18:40 answering member 4067 label Biography information for Steve Brine
tabling member	4249 label Biography information for Anne Marie Morris